Koya Medical, a healthcare company focused on developing breakthrough treatments for lymphedema and venous diseases, announced today that its wearable, active compression therapy system for lymphedema—Dayspring™— was issued new billing codes by the Center of Medicare & Medicaid Services (CMS) in accordance with the Healthcare Common Procedure Coding System (HCPCS). Dayspring is the first wearable and mobility-enabling active compression treatment cleared by the U.S. Food & Drug Administration (FDA) to treat lymphedema and other similar conditions. Providers may begin using the new codes on October 1, 2021.
Lymphedema is a serious chronic condition, for which there is no cure. Preexisting reimbursement codes have covered traditional pneumatic or air-based compression systems for more than three decades. Dayspring’s new code addresses this first significant advancement in active compression technology and supports the mobility for the user, by delivering compression through Koya’s proprietary Flexframe™ technology, which uses electromechanical means and a mobile power source to deliver therapeutic pressures while enabling mobility and movements for patients.
Dayspring is unique from other active compression treatments and includes a low-profile active garment made of soft, breathable mesh using Flexframe technology; a smart, rechargeable, hand-held controller that can be worn on a lanyard; and a mobile app that allows users or their clinicians to individualize treatment options and track utilization.